List of Sustol drug patents
Sustol is owned by Heron Theraps Inc.
Sustol contains Granisetron.
Sustol has a total of 5 drug patents out of which 0 drug patents have expired.
Sustol was authorised for market use on 09 August, 2016.
Sustol is available in injection, extended release;subcutaneous dosage forms.
Sustol can be used as treatment or prevention of nausea and vomiting, prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy.
The generics of Sustol are possible to be released after 28 September, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8252304 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(1 year, 7 months from now) | |
| US8715710 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(1 year, 7 months from now) | |
| US10357570 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(1 year, 7 months from now) | |
| US8252305 | HERON THERAPS INC | Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron |
Sep, 2024
(1 year, 7 months from now) | |
| US9913910 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(1 year, 7 months from now) | |
Drugs and Companies using GRANISETRON ingredient
Market Authorisation Date: 09 August, 2016
Treatment: Prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy; Treatment or prevention of nausea and vomiting
Dosage: INJECTION, EXTENDED RELEASE;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic